newsfilter
← Latest News
GlobeNewswire·

Kirby McInerney LLP Alerts Investors Who Acquired Capricor Therapeutics, Inc. CAPR Securities Between December 17, 2025 and July 26, 2026 of Pending Lawsuit

CAPR
  • Kirby McInerney LLP notifies Capricor Therapeutics investors of the September 28, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action.
  • The lawsuit covers investors who purchased securities between December 17, 2025, & July 26, 2026, alleging Capricor failed to disclose changes to the statistical analysis plan for Deramiocel without FDA agreement.
  • On July 27, 2026, FDA documents revealed the statistical plan changes were not reviewed or agreed upon prior to the BLA submission, causing Capricor stock to fall 64% to $7.00 per share.
  • On July 30, 2026, an FDA advisory committee voted 9-3 that evidence did not support Deramiocel efficacy, causing stock to drop another 36% to $4.19 per share.
  • Investors who suffered losses are encouraged to contact Lauren Molinaro at Kirby McInerney LLP via email or the contact form at no cost to discuss their rights.
  • The lead plaintiff oversees litigation strategy & settlements, & courts do not consider applications filed after the specified deadline.